Several compounds have been evaluated in preclinical models as potential therapeutic targets in PD, including recombinant DJ-1 protein [245], AAV-DJ-1 [245], and the short DJ-1-based peptide ND-13 [246], and DJ-1-binding compounds UCP0054277 andUCP0054278 [247,248,249,250,251]. The gene discussed is PARK7; the disease is Parkinson disease.